Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK)

Historical Holders from Q1 2014 to Q3 2025

Symbol
ANIK on Nasdaq
CUSIP
035255108
Type / Class
Equity / Common Stock, par value $0.01 per share
Shares outstanding
14.4M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
12.2M
Holdings value
$115M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
113
Number of buys
67
Number of sells
-38
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Trigran Investments, Inc. 11.2% $15.2M 1.62M Trigran Investments, Inc. Sep 30, 2025
Caligan Partners LP 9.95% $14.4M 1.44M Caligan Partners LP Nov 19, 2025
BlackRock, Inc. 6.8% -34.5% $14.1M -$8.74M 963K -38.2% BlackRock, Inc. Mar 31, 2025
BlackRock Portfolio Management LLC 5.5% $7.45M 793K BlackRock Portfolio Management LLC Sep 30, 2025
DIMENSIONAL FUND ADVISORS LP 4.5% $9.66M 657K Dimensional Fund Advisors LP Dec 31, 2024

Institutional Holders of Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 12.2M $115M -$5.97M $9.40 113
2025 Q2 12.7M $134M -$1.53M $10.58 101
2025 Q1 12.7M $191M +$2.18M $15.03 107
2024 Q4 12.5M $206M -$14.1M $16.46 108
2024 Q3 13.1M $324M -$7.57M $24.70 121
2024 Q2 13.2M $335M -$3.27M $25.33 113
2024 Q1 13.4M $340M +$4.32M $25.40 118
2023 Q4 13.3M $300M +$7.01M $22.66 116
2023 Q3 13M $242M -$5.56M $18.63 116
2023 Q2 13.1M $340M +$436K $25.98 116
2023 Q1 13.1M $376M -$1.05M $28.72 119
2022 Q4 13.1M $388M -$23.7M $29.60 124
2022 Q3 13.5M $321M -$1.53M $23.80 114
2022 Q2 13.5M $302M -$733K $22.32 118
2022 Q1 13.6M $341M +$997K $25.11 114
2021 Q4 13.5M $483M +$10.3M $35.83 125
2021 Q3 13.2M $560M -$491K $42.56 128
2021 Q2 13.1M $569M -$4.27M $43.29 133
2021 Q1 13.3M $543M -$15.4M $40.79 145
2020 Q4 13.5M $613M +$244K $45.26 157
2020 Q3 13.6M $481M -$8.43M $35.39 155
2020 Q2 13.8M $520M +$35.1M $37.73 157
2020 Q1 13M $375M -$24M $28.91 159
2019 Q4 13.4M $697M -$12.7M $51.85 188
2019 Q3 13.7M $750M -$18.3M $54.89 191
2019 Q2 14M $570M +$37.4M $40.62 166
2019 Q1 13.3M $403M +$13.8M $30.24 155
2018 Q4 12.8M $429M -$13.5M $33.61 156
2018 Q3 13.1M $554M -$31.4M $42.18 155
2018 Q2 13.9M $446M +$47.5M $32.00 163
2018 Q1 12.4M $616M +$15.3M $49.72 164
2017 Q4 12.4M $670M -$1.45M $53.91 165
2017 Q3 12.4M $719M +$3.29M $58.00 165
2017 Q2 12.4M $610M +$27M $49.34 157
2017 Q1 11.9M $515M +$108M $43.44 154
2016 Q4 11M $538M -$2.6M $48.96 153
2016 Q3 11.1M $530M -$20.7M $47.85 159
2016 Q2 11.5M $617M -$31.5M $53.65 159
2016 Q1 12.1M $542M -$12.6M $44.72 161
2015 Q4 12.4M $474M -$1.41M $38.16 149
2015 Q3 12.5M $397M +$11.1M $31.83 136
2015 Q2 12.1M $401M -$15.2M $33.03 136
2015 Q1 12.3M $505M +$17.8M $41.17 157
2014 Q4 11.9M $483M +$36.8M $40.74 160
2014 Q3 11M $405M +$34.1M $36.66 152
2014 Q2 9.99M $463M -$6.56M $46.33 161
2014 Q1 10.2M $417M +$54.1M $41.10 152